ByteDance’s AI drug unit’s rapid unicorn status highlights the growing investor confidence and potential disruption in AI-driven drug discovery.
The post ByteDance completes $290M fundraising for AI drug unit at $1.5B valuation appeared first on Crypto Briefing.